# This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)

> **NCT04417036** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 90 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** BAY1097761 Active Dose 1
- **OTHER:** Placebo to BAY1097761
- **DRUG:** BAY1097761 Active Dose 2

## Key facts

- **NCT ID:** NCT04417036
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-07
- **Primary completion:** 2022-12-28
- **Final completion:** 2022-12-28
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Terminated (based on Part A results, Bayer decided to not continue investigating BAY 1097761 further in Part B; this was not due to any safety data for BAY 1097761)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417036, "This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04417036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*